NPHP4

Across TCGA pan-cancer cohorts, NPHP4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NPHP4 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher NPHP4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NPHP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BRCA, HNSC, and KICH are the cancer types where NPHP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.747	0.925	<.001	30	view →
HNSC	OS	Median	III,IV	0.363	0.748	<.001	27	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	All	0.964	0.646	.006	12	view →
PRAD	DFS	Median	All	0.617	0.886	.038	6	view →
SCLC	DFS	Median	II,III,IV	0.192	0.611	.025	6	view →
SKCM	OS	Median	All	1.000	0.866	.018	5	view →
STAD	DFS	Median	II,III,IV	0.871	0.367	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NPHP4–BRCA (OS)

Open the BRCA breakdown →